Effect of statins on blood pressure: Analysis on adverse events released by FDA

References

• Prospective Studies C, Lewington S, Whitlock G, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007;370:1829–1839.
   PubMed Web of Science ®Google Scholar
• Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;1:CD004816.
   PubMed Web of Science ®Google Scholar
• Buhaescu I, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem 2007;40:575–584.
   PubMed Web of Science ®Google Scholar
• Istvan E. Statin inhibition of HMG-CoA reductase: a 3-dimensional view. Atheroscler Suppl 2003;4:3–8.
   PubMed Web of Science ®Google Scholar
• Hyyppa MT, Kronholm E, Virtanen A, et al. Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial. Psychoneuroendocrinology 2003;28:181–194.
   PubMed Web of Science ®Google Scholar
• Davidson MH. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. Drugs 2001;61:197–206.
   PubMed Web of Science ®Google Scholar
• Chopra V, Choksi PU, Cavusoglu E. Beyond lipid lowering: the anti-hypertensive role of statins. Cardiovasc Drugs Ther 2007;21:161–169.
   PubMed Web of Science ®Google Scholar
• Strazzullo P, Kerry SM, Barbato A, et al. Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials. Hypertension 2007;49:792–798.
   PubMed Web of Science ®Google Scholar
• Abetel G, Poget PN, Bonnabry JP. [Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin). A pilot study]. Schweiz Med Wochenschr 1998;128:272–277.
   PubMedGoogle Scholar
• Correa V, Jr., Fuchs FD, Moreira LB, et al. Blood pressure-lowering effect of simvastatin: a placebo-controlled randomized clinical trial with 24-h ambulatory blood pressure monitoring. J Hum Hypertens 2014;28:62–67.
   PubMed Web of Science ®Google Scholar
• Branchi A, Fiorenza AM, Torri A, et al. Effects of simvastatin on blood pressure in hypercholesterolemic patients: An open-label study in patients with hypertension or normotension. Curr Ther Res Clin Exp 2004;65:239–254.
   PubMed Web of Science ®Google Scholar
• Briasoulis A, Agarwal V, Valachis A, Messerli FH. Antihypertensive effects of statins: a meta-analysis of prospective controlled studies. J Clin Hypertens 2013;15:310–320.
   Web of Science ®Google Scholar
• Giannattasio C, Mangoni AA, Failla M, et al. Impaired radial artery compliance in normotensive subjects with familial hypercholesterolemia. Atherosclerosis 1996;124:249–260.
   PubMed Web of Science ®Google Scholar
• Baldassarre D, Busnach G, Amato M, et al. Effect of plasma cholesterol reduction by pravastatin on the functional properties of forearm arteries in hypercholesterolemic patients. Nutr Metab Cardiovasc Dis 1999;9:108–117.
   PubMed Web of Science ®Google Scholar
• Banach M, Nikfar S, Rahimi R, et al. The effects of statins on blood pressure in normotensive or hypertensive subjects–a meta-analysis of randomized controlled trials. Int J of Cardiol 2013;168:2816–2824.
   PubMed Web of Science ®Google Scholar
• Feldstein CA. Statins in hypertension: are they a new class of antihypertensive agents? Am J Ther 2010;17:255–262.
   PubMed Web of Science ®Google Scholar
• Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002;36:288–295.
   PubMed Web of Science ®Google Scholar
• Shu M, Zai X, Zhang B, et al. Hypothyroidism side effect in patients treated with sunitinib or sorafenib: Clinical and structural analyses. PloS One 2016;11:e0147048.
   PubMed Web of Science ®Google Scholar
• Kass-Hout TA, Xu Z, Mohebbi M, et al. OpenFDA: an innovative platform providing access to a wealth of FDA’s publicly available data. J Am Medical Inf Assoc: JAMIA 2015; 23(3):596–600.
   Google Scholar
• Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 2004;13:519–523.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–1558.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–634.
   PubMed Web of Science ®Google Scholar
• Cortes J, Mauro M, Steegmann JL, et al. Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System. Am J Hematol 2015;90:E66–E72.
   PubMed Web of Science ®Google Scholar
• Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004;3:673–683.
   PubMed Web of Science ®Google Scholar
• Poulter NR, Prabhakaran D, Caulfield M. Hypertension. Lancet 2015;386:801–812.
   PubMed Web of Science ®Google Scholar
• Campbell NR, Lackland DT, Lisheng L, et al. Using the Global Burden of Disease study to assist development of nation-specific fact sheets to promote prevention and control of hypertension and reduction in dietary salt: a resource from the World Hypertension League. J Clin Hypertens (Greenwich) 2015;17:165–167.
   PubMed Web of Science ®Google Scholar
• Liu R, Singh N, Tawa GJ, et al. Exploiting large-scale drug-protein interaction information for computational drug repurposing. BMC Bioinf 2014;15:210.
   PubMed Web of Science ®Google Scholar
• Borghi C, Dormi A, Veronesi M, et al. Use of lipid-lowering drugs and blood pressure control in patients with arterial hypertension. J Clin Hypertens (Greenwich) 2002;4:277–285.
   PubMedGoogle Scholar
• Tonolo G, Melis MG, Formato M, et al. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000;30:980–987.
   PubMed Web of Science ®Google Scholar
• Borghi C, Prandin MG, Costa FV, et al. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000; 35:549-55.
   PubMed Web of Science ®Google Scholar
• Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999; 33:234-41.
   PubMed Web of Science ®Google Scholar
• Ide H, Fujiya S, Aanuma Y, Agishi Y. Effects of simvastatin, an HMG-CoA reductase inhibitor, on plasma lipids and steroid hormones. Clin Ther 1990;12:410–420.
   PubMed Web of Science ®Google Scholar
• Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711–2719.
   PubMed Web of Science ®Google Scholar
• Nickenig G, Baumer AT, Temur Y, et al. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999;100:2131–2134.
   PubMed Web of Science ®Google Scholar
• Rise P, Pazzucconi F, Sirtori CR, Galli C. Statins enhance arachidonic acid synthesis in hypercholesterolemic patients. Nutr Metab Cardiovasc Dis 2001;11:88–94.
   PubMed Web of Science ®Google Scholar
• Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011;34:1369–1371.
   PubMed Web of Science ®Google Scholar
• Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf 2009;18:512–518.
   PubMed Web of Science ®Google Scholar